NPC1L1 drugs for Atherosclerotic Cardiovascular Disease
3 tracked NPC1L1 drugs in the Atherosclerotic Cardiovascular Disease race. The class explanation lives on the NPC1L1 page; the full indication pipeline across every mechanism is on the Atherosclerotic Cardiovascular Disease page.
3 Phase 3
Head-to-head evidence: Ezetimibe vs Hyzetimibe · Ezetimibe vs Obicetrapib/ezetimibe (Evlarco) · Hyzetimibe vs Obicetrapib/ezetimibe (Evlarco)